Dallas, Texas 04/16/2014 (FINANCIALSTRENDS) – Zogenix, Inc. (NASDAQ:ZGNX) , the San Diego based drug maker disclosed that a U.S District Court in Massachusetts has stayed the coming into effect of the state governments order which banned the sale of its approved drug Zohydro Er . The court ordered status quo on the sale of the product citing constitutional provisions which govern this circumstance. The court order will be effective next week, starting 22nd April.
The district court in its detailed order observed that the drug in question Zohydro™ ER which is also known by its chemical composition “hydrocodone bitartrate” and sold in a capsule format to treat Opioid, had received approval from the U.S Food and Drug Administration after a thorough investigation into the efficacy and safety aspects.
This being the case, the court felt that allowing individual states to reverse or stand in judgment on the official decisions of Food and Drug Administration, which is the constitutionally mandated body which has been set up by the Federal Government for the express purpose of regulating the manufacture and sale of drugs in U.S would create a wrong precedent in regard to the existing federal laws which guarantee access of new prescription drugs to suffering patients.
Zogenix, Inc. (NASDAQ:ZGNX) Chief Executive Officer and Director Roger L. Hawley while speaking to the press post the judgement, expressed his relief at the favourable verdict and has been quoted to have said that, “Today’s legal ruling was a positive step forward for Massachusetts patients. We invite concerned officials to engage with us to discuss fair and appropriate safeguards for pain medications like Zohydro ER rather than seeking to ban or restrict one specific treatment.”
He went on to assure all stake holders and the patients that his firm will continue to further invest in R &D to improve its formulations designed to provide relief to sufferers of acute and chronic pain and make sure these are available to the needs through all states of U.S.